公开(公告)号：US12247080B2

公开(公告)日：2025-03-11

申请号：US17108373

申请日：2020-12-01

Applicant: GENMAB B.V.

Inventor： Marije Overdijk ,  Kristin Strumane ,  Rik Rademaker ,  Esther Breij ,  Janine Schuurman ,  Paul Parren

IPC: A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C12N15/62 ,  A61K38/00 ,  A61K39/00 ,  C07K14/715 ,  C07K16/46

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

公开(公告)号：US12173076B2

公开(公告)日：2024-12-24

申请号：US16482747

申请日：2018-02-12

Applicant: GENMAB B.V.

Inventor： Frank Beurskens ,  Marije Overdijk ,  Annieck M. Diks ,  Rob De Jong ,  Kristin Strumane ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/28 ,  C07K16/10

Abstract: As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.

公开(公告)号：US11795214B2

公开(公告)日：2023-10-24

申请号：US16399424

申请日：2019-04-30

Applicant: GENMAB A/S

Inventor： Paul Parren ,  Patrick Van Berkel ,  Ewald Van Den Bremer

IPC: C07K16/18 ,  C07K16/00 ,  G01N33/50 ,  G01N33/68

CPC classification number: C07K16/18 ,  C07K16/00 ,  G01N33/5014 ,  G01N33/6854 ,  C07K2317/51 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/734

Abstract: Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described.

公开(公告)号：US11578141B2

公开(公告)日：2023-02-14

申请号：US16667369

申请日：2019-10-29

Applicant: GENMAB A/S

Inventor： Joost J. Neijssen ,  Joyce I. Meesters ,  Bart De Goeij ,  Aran Frank Labrijn ,  Paul Parren ,  Janine Schuurman

IPC: C07K16/46 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  A61K47/68 ,  A61K39/395 ,  C07K1/113 ,  A61K39/00

Abstract: Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.

公开(公告)号：US11512140B2

公开(公告)日：2022-11-29

申请号：US16548883

申请日：2019-08-23

Applicant: GENMAB A/S

Inventor： Joost J. Neijssen ,  Bart De Goeij ,  Edward Norbert Van Den Brink ,  Aran Frank Labrijn ,  Rene Hoet ,  Janine Schuurman ,  Paul Parren ,  Jan Van De Winkel

IPC: C07K16/30 ,  G01N33/574 ,  A61P35/00 ,  A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  C07K16/40 ,  A61K39/00

Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US11512137B2

公开(公告)日：2022-11-29

申请号：US16872140

申请日：2020-05-11

Applicant: GENMAB HOLDING B.V.

Inventor： Simone Oostindie ,  Frank Beurskens ,  Esther Breij ,  Edward Van Den Brink ,  Andreas Hollenstein ,  Marije Overdijk ,  Margaret Lindorfer ,  Ronald Taylor ,  Paul Parren ,  Hilma Van Der Horst ,  Martine E. D. Chamuleau ,  Tuna Mutis

IPC: C07K16/28 ,  A61P35/00 ,  A61K49/00 ,  G01N33/68 ,  A61K39/00

Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.

公开(公告)号：US11485796B2

公开(公告)日：2022-11-01

申请号：US16783720

申请日：2020-02-06

Applicant: GENMAB A/S

Inventor： Aran Frank Labrijn ,  Joyce I. Meesters ,  Joost J. Neijssen ,  Edward Norbert Van Den Brink ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/00 ,  C07K16/40 ,  C07K16/28 ,  C07K16/10 ,  C07K16/36 ,  C07K16/32 ,  C07K16/12 ,  A61K39/00

Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

公开(公告)号：US11459395B2

公开(公告)日：2022-10-04

申请号：US17172694

申请日：2021-02-10

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Ugur Sahin ,  Friederike Gieseke ,  Alexander Muik ,  Christian Grunwitz ,  Edward Van den Brink ,  Dennis Verzijl

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US11034772B2

公开(公告)日：2021-06-15

申请号：US17066190

申请日：2020-10-08

Applicant: GENMAB HOLDING B.V.

Inventor： Simone Oostindie ,  Frank Beurskens ,  Esther Breij ,  Edward Van Den Brink ,  Andreas Hollenstein ,  Marije Overdijk ,  Margaret Lindorfer ,  Ronald Taylor ,  Paul Parren ,  Hilma Van Der Horst ,  Martine E. D. Chamuleau ,  Tuna Mutis

IPC: C07K16/28 ,  A61P35/00 ,  A61K49/00 ,  G01N33/68 ,  A61K39/00

Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.

公开(公告)号：US10968280B2

公开(公告)日：2021-04-06

申请号：US16779011

申请日：2020-01-31

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Ugur Sahin ,  Friederike Gieseke ,  Alexander Muik ,  Christian Grunwitz

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.